Buchumschlag

Seladelpar Improved Itch, Itch‐Related Sleep Disturbance and Measures of Fatigue in Patients With Primary Biliary Cholangitis and Pruritus in the Phase 3 RESPONSE Trial

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Cynthia Levy, David E. J. Jones, Marlyn J. Mayo, Christopher L. Bowlus, Kris V. Kowdley, Gideon M. Hirschfield, Jie Liu, Caroline Burk, Susheela Carroll, Daria B. Crittenden, Andreas E. Kremer
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2026
Schlagworte:	Alimentary Pharmacology & Therapeutics
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Review Article: Targeting Peroxisome Proliferator‐Activated Receptors in Primary Biliary Cholangitis
von: Jörn M. Schattenberg, et al.
Veröffentlicht: (2026)

Longitudinal Relationship Between Elevated Liver Biochemical Tests and Negative Clinical Outcomes in Primary Biliary Cholangitis: A Population‐Based Study
von: Kris V. Kowdley, et al.
Veröffentlicht: (2025)

Research Communication: Real‐World Clinical Experience With Seladelpar in Primary Biliary Cholangitis
von: Selena Z. Kuo, et al.
Veröffentlicht: (2025)

Editorial: Patient Reported Outcomes Provide Insight Into Disease Severity for People Living With Primary Sclerosing Cholangitis
von: Aisha Alawi, et al.
Veröffentlicht: (2025)

Letter: Myokines Are Also Associated With Disease Course in Primary Biliary Cholangitis
von: Leyu Zhou, et al.
Veröffentlicht: (2024)

Letter: Incremental Value and Stratified Interpretation of Dual Autoantibody Positivity in Primary Biliary Cholangitis
von: Ao Gao, et al.
Veröffentlicht: (2026)

Lymphocyte‐to‐Monocyte Ratio as a Predictor of Recompensation in Patients With Decompensated Primary Biliary Cholangitis
von: Huiying Lin, et al.
Veröffentlicht: (2025)

A Nationwide Assessment of Anticholestatic Therapy Uptake in Patients With Primary Biliary Cholangitis: Opportunities for Optimisation
von: Ellen Werner, et al.
Veröffentlicht: (2026)

Long‐Term Use of Fenofibrate as Second‐Line Therapy in Primary Biliary Cholangitis: A Retrospective Study
von: Mariko Maxwell, et al.
Veröffentlicht: (2026)

Letter: Incremental Value and Stratified Interpretation of Dual Autoantibody Positivity in Primary Biliary Cholangitis. Authors' Reply
von: Hong‐Li Liu, et al.
Veröffentlicht: (2026)

Non‐Response to Obeticholic Acid Is Associated With Heightened Risks of Developing Clinical Events in Primary Biliary Cholangitis
von: Nadir Abbas, et al.
Veröffentlicht: (2025)

Letter: Increased Prevalence of Visceral Obesity in Nonresponder Patients With Primary Biliary Cholangitis Based on Computed Tomography
von: Bo Li, et al.
Veröffentlicht: (2024)

Letter on ‘Non‐Response to Obeticholic Acid Is Associated With Heightened Risks of Developing Clinical Events in Primary Biliary Cholangitis’
von: Yi Pei, et al.
Veröffentlicht: (2025)

Letter: Increased Prevalence of Visceral Obesity in Nonresponder Patients With Primary Biliary Cholangitis Based on Computed Tomography—Authors' Reply
von: Conrado Fernandez‐Rodriguez, et al.
Veröffentlicht: (2024)

Editorial: When and What to Ask—Capturing the Symptoms Experienced by Patients With PSC
von: Christopher L. Bowlus, et al.
Veröffentlicht: (2025)

Dual Positivity for AMA / AMA ‐ M2 and Anti‐gp210/sp100 Shows Highest Diagnostic Value for Primary Biliary Cholangitis
von: Hong‐Li Liu, et al.
Veröffentlicht: (2026)

Quantitative MRCP and metrics of bile duct disease over time in patients with primary sclerosing cholangitis: A prospective study
von: Palak J. Trivedi, et al.
Veröffentlicht: (2024)

Letter: Therapeutic Targeting of PPARs in PBC —Additional Considerations. Authors' Reply
von: J. M. Schattenberg, et al.
Veröffentlicht: (2026)

Primary Sclerosing Cholangitis in the Absence of Inflammatory Bowel Disease Increases the Risk of Colorectal Cancer: A Multi‐Centre Propensity Score Matched Analysis
von: Saqr Alsakarneh, et al.
Veröffentlicht: (2025)

Editorial: Low‐Level Viraemia in Chronic Hepatitis B—A Benign State or Missed Opportunity?
von: Miriam T. Levy
Veröffentlicht: (2026)

Prevalence and Burden of Fatigue Across Disorders of Gut–Brain Interaction: Results From the Rome Foundation Global Epidemiology Study
von: Fleur Veldman, et al.
Veröffentlicht: (2026)

Reduced Descending Itch Inhibition in Peripheral Neuropathy Patients With Chronic Pruritus
von: Jonas Eck, et al.
Veröffentlicht: (2026)

Editorial: Are changes in quantitative biliary metrics the first sign of progression in primary sclerosing cholangitis?
von: John E. Eaton, et al.
Veröffentlicht: (2024)

Editorial: High‐Grade Dysplasia in Colonic Inflammatory Bowel Disease Is Associated With a High Risk of Synchronous or Metachronous Colorectal Cancer—Authors' Reply
von: Monica E. W. Derks, et al.
Veröffentlicht: (2025)

Review article: Faecal biomarkers for assessing small intestinal damage in coeliac disease and environmental enteropathy
von: Laura Kivelä, et al.
Veröffentlicht: (2024)

Applying Lyon consensus criteria in the work‐up of patients with extra‐oesophageal symptoms – A multicentre retrospective study
von: Francesco Calabrese, et al.
Veröffentlicht: (2024)

Editorial: Diagnosis of GERD in patients with extra‐oesophageal symptoms—still a long way to go… Authors' reply'
von: Francesco Calabrese, et al.
Veröffentlicht: (2024)

Analysis of Antroduodenal Motility in Patients With Hypermobility Spectrum Disorders/Hypermobile Ehlers–Danlos Syndrome
von: Kim W. E. Sweerts, et al.
Veröffentlicht: (2025)

Letter: Is Enteric Neuropathy Absent in Hypermobility Spectrum Disorders/Hypermobile Ehler–Danlos Syndrome? Authors' Reply
von: Kim W. E. Sweerts, et al.
Veröffentlicht: (2025)

Blood Eosinophils Are Accurate Biomarkers for the Management of Eosinophilic Oesophagitis: Prospective, Multi‐Centre Study
von: Pierfrancesco Visaggi, et al.
Veröffentlicht: (2026)

Editorial: Optimal Treatment for Older Patients With Inflammatory Bowel Disease: How to Detect and Manage Frailty? Authors' Reply
von: A. B. Fons, et al.
Veröffentlicht: (2026)

Functional Dyspepsia and Its Subgroups: Prevalence and Impact in the Rome IV Global Epidemiology Study
von: J. Tack, et al.
Veröffentlicht: (2025)

Development of hepatic fibrosis in common variable immunodeficiency‐related porto‐sinusoidal vascular disorder
von: Julian Hercun, et al.
Veröffentlicht: (2024)

Systematic Review: Incidence of Liver‐Related Events in People Living With Hepatitis Delta Virus
von: Laura E. Telep, et al.
Veröffentlicht: (2025)

Clinical Trial: Association Between Early Disease Clearance and Long‐Term Outcomes—4‐Year Results From the Phase 3 UNIFI Study of Ustekinumab in Ulcerative Colitis
von: Silvio Danese, et al.
Veröffentlicht: (2025)

Surviving Hepatitis C—Understanding Death and Survival Beyond Cure
von: Paul J. Clark, et al.
Veröffentlicht: (2025)

Research Communication: Teriflunomide Does Not Affect Gluten‐Specific T‐Cell Activity in Coeliac Disease—A Randomised, Placebo‐Controlled Trial
von: Louise F. Risnes, et al.
Veröffentlicht: (2025)

Maladaptive weight control and eating behaviours in female adolescents/young adults are associated with increased risk of irritable bowel syndrome in adulthood: Results from the Growing Up Today Study (GUTS)
von: Keming Yang, et al.
Veröffentlicht: (2024)

Editorial: Intestinal Ultrasound for the Assessment of Constipation—Out of the Shadows?
von: J. M. B. W. Vos, et al.
Veröffentlicht: (2025)

Editorial: Personalising the Low FODMAP Diet to Achieve Therapeutic Benefit Whilst Reducing Burden and Maintaining Dietary Diversity in Irritable Bowel Syndrome. Authors' Reply
von: E. Coss‐Adame, et al.
Veröffentlicht: (2026)